title: Rapid symptomatic improvement in gefitinib-treated patients with EGFR-mutated lung cancer: possible role of downregulation of inflammatory molecules?
authors: Evgeny N
authors: EN
authors: Suspitsin
authors: Evgeny V
authors: EV
authors: Levchenko
authors: Fedor V
authors: FV
authors: Moiseyenko
authors: Alexandr O
authors: AO
authors: Ivantsov
authors: Samira A
authors: SA
authors: Radzhabova
authors: Dmitry E
authors: DE
authors: Matsko
authors: Vladimir M
authors: VM
authors: Moiseyenko
authors: Evgeny N
authors: EN
authors: Imyanitov
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004252:DNA Mutational Analysis; D015536:Down-Regulation / Q000187:drug effects* / Q000235:genetics*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics*; D005260:Female; D000077156:Gefitinib; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D008207:Lymphatic Metastasis; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D011799:Quinazolines / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
chemical_list: D000970:Antineoplastic Agents; D018836:Inflammation Mediators; D011799:Quinazolines; C512478:EGFR protein, human; D066246:ErbB Receptors; D000077156:Gefitinib